<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196377</url>
  </required_header>
  <id_info>
    <org_study_id>100725</org_study_id>
    <secondary_id>K23HL080005</secondary_id>
    <nct_id>NCT01196377</nct_id>
  </id_info>
  <brief_title>Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study</brief_title>
  <acronym>OARS</acronym>
  <official_title>Personalized Medicine, Biomarker-based Study of Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our overall objective is to model a pediatric Acute Asthma Clinical Decision Rule (ADR) for
      personalized medicine by identification of treatment-response phenotypes that are important
      determinants of outcome. The Specific Aim of this study is to determine the feasibility of
      this approach by enrolling a pilot cohort of 16 participants in this DBRCT of 4 different
      albuterol treatment regimens, 2 of which will use 10mg/hr and 2 of which will use 25mg/hr.
      Within these dosages there will be a pulsed-treatment regimen and a continuous regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to determine the feasibility of this approach by enrolling a
      pilot cohort of 16 participants in this DBRCT of 4 different albuterol treatment regimens, 2
      of which will use 10mg/hr and 2 of which will use 25mg/hr. Participants are randomized in
      randomly permuted blocks of four. Within these dosages there will be a pulsed-treatment
      regimen and a continuous regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>%FEV1</measure>
    <time_frame>2 hours</time_frame>
    <description>% predicted forced expiratory volume in 1-second as a measure of airway obstruction</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Acute Asthma</condition>
  <arm_group>
    <arm_group_label>Nebulized albuterol 10mg/hr continuous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active control arm, 10mg/hr continuous.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg/hr pulsed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental 10mg/hr pulsed albuterol regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25mg/hr continuous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental 25mg/hr continuous albuterol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25mg/hr pulsed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental 25mg/hr pulsed albuterol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol</intervention_name>
    <description>Nebulized albuterol</description>
    <arm_group_label>Nebulized albuterol 10mg/hr continuous</arm_group_label>
    <arm_group_label>10mg/hr pulsed</arm_group_label>
    <arm_group_label>25mg/hr continuous</arm_group_label>
    <arm_group_label>25mg/hr pulsed</arm_group_label>
    <other_name>proventil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Doctor diagnosed asthma

          -  Acute asthma exacerbation

          -  Treatment with systemic corticosteroids and nebulized albuterol

          -  Ages 5 to 17 years

        Exclusion Criteria:

          -  Other acute or chronic lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald H Arnold, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University School of Medicine</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <results_first_submitted>December 10, 2014</results_first_submitted>
  <results_first_submitted_qc>September 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2017</results_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Donald H Arnold</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics and Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Acute asthma</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We recruited 16 patients ages 5 to 17 years for this double blind randomized trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nebulized Albuterol 10mg/hr Continuous</title>
          <description>Active control arm, 10mg/hr continuous.</description>
        </group>
        <group group_id="P2">
          <title>10mg/hr Pulsed</title>
          <description>Experimental 10mg/hr pulsed albuterol regimen.</description>
        </group>
        <group group_id="P3">
          <title>25mg/hr Continuous</title>
          <description>Experimental 25mg/hr continuous albuterol.</description>
        </group>
        <group group_id="P4">
          <title>25mg/hr Pulsed</title>
          <description>Experimental 25mg/hr pulsed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nebulized Albuterol 10mg/hr Continuous</title>
          <description>Active control arm, 10mg/hr continuous.</description>
        </group>
        <group group_id="B2">
          <title>10mg/hr Pulsed</title>
          <description>Experimental 10mg/hr pulsed albuterol regimen.</description>
        </group>
        <group group_id="B3">
          <title>25mg/hr Continuous</title>
          <description>Experimental 25mg/hr continuous albuterol.</description>
        </group>
        <group group_id="B4">
          <title>25mg/hr Pulsed</title>
          <description>Experimental 25mg/hr pulsed</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.8" spread="2"/>
                    <measurement group_id="B2" value="7.9" spread="2"/>
                    <measurement group_id="B3" value="7.6" spread="4"/>
                    <measurement group_id="B4" value="7.7" spread="2"/>
                    <measurement group_id="B5" value="7.7" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>%FEV1</title>
        <description>% predicted forced expiratory volume in 1-second as a measure of airway obstruction</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebulized Albuterol 10mg/hr Continuous</title>
            <description>Active control arm, 10mg/hr continuous.
Albuterol: Nebulized albuterol</description>
          </group>
          <group group_id="O2">
            <title>10mg/hr Pulsed</title>
            <description>Experimental 10mg/hr pulsed albuterol regimen.
Albuterol: Nebulized albuterol</description>
          </group>
          <group group_id="O3">
            <title>25mg/hr Continuous</title>
            <description>Experimental 25mg/hr continuous albuterol.
Albuterol: Nebulized albuterol</description>
          </group>
          <group group_id="O4">
            <title>25mg/hr Pulsed</title>
            <description>Experimental 25mg/hr pulsed
Albuterol: Nebulized albuterol</description>
          </group>
        </group_list>
        <measure>
          <title>%FEV1</title>
          <description>% predicted forced expiratory volume in 1-second as a measure of airway obstruction</description>
          <units>%-predicted</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, pretreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="17" upper_limit="25"/>
                    <measurement group_id="O2" value="34" lower_limit="19" upper_limit="41"/>
                    <measurement group_id="O3" value="26" lower_limit="16" upper_limit="36"/>
                    <measurement group_id="O4" value="31" lower_limit="14" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-hours (post-treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="32" upper_limit="48"/>
                    <measurement group_id="O2" value="47" lower_limit="17" upper_limit="77"/>
                    <measurement group_id="O3" value="67" lower_limit="61" upper_limit="73"/>
                    <measurement group_id="O4" value="44" lower_limit="34" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 hours</time_frame>
      <desc>Report is to data safety and monitoring committee and IRB.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nebulized Albuterol 10mg/hr Continuous</title>
          <description>Active control arm, 10mg/hr continuous.</description>
        </group>
        <group group_id="E2">
          <title>10mg/hr Pulsed</title>
          <description>Experimental 10mg/hr pulsed albuterol regimen.</description>
        </group>
        <group group_id="E3">
          <title>25mg/hr Continuous</title>
          <description>Experimental 25mg/hr continuous albuterol.</description>
        </group>
        <group group_id="E4">
          <title>25mg/hr Pulsed</title>
          <description>Experimental 25mg/hr pulsed</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations: small sample size and not powered to detect differences in outcomes (pilot feasibility study).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Donald H Arnold</name_or_title>
      <organization>Vanderbilt University School of Medicine</organization>
      <phone>6155790516</phone>
      <email>don.arnold@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

